Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C32H38Cl2N10O4.ClH |
| Molecular Weight | 734.076 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CN1C=C(NC(=O)C2=CC(NC(=O)C3=CC(NC(=O)C4=CC=C(C=C4)N(CCCl)CCCl)=CN3C)=CN2C)C=C1C(=O)NCCC(N)=N
InChI
InChIKey=BLSOATWWAGIRGE-UHFFFAOYSA-N
InChI=1S/C32H38Cl2N10O4.ClH/c1-41-18-22(14-25(41)30(46)37-11-8-28(35)36)39-32(48)27-16-23(19-43(27)3)40-31(47)26-15-21(17-42(26)2)38-29(45)20-4-6-24(7-5-20)44(12-9-33)13-10-34;/h4-7,14-19H,8-13H2,1-3H3,(H3,35,36)(H,37,46)(H,38,45)(H,39,48)(H,40,47);1H
| Molecular Formula | C32H38Cl2N10O4 |
| Molecular Weight | 697.615 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Tallimustine (also known as FCE 24517), an alkylating benzoyl mustard derivative of distamycin A that was studied as an anti-tumor agent. Tallimustine participated in phase I clinical trial in patients with advanced cancer. As a result, the was obtained the recommended Phase II dosage for tallimustine. However, the further development of this drug was discontinued.
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Accumulation of gamma-globin mRNA and induction of erythroid differentiation after treatment of human leukaemic K562 cells with tallimustine. | 2001-06 |
|
| A phase I and pharmacokinetic study of tallimustine [PNU 152241 (FCE 24517)] in patients with advanced cancer. | 1998-01 |
Patents
Sample Use Guides
Patients with advanced solid tumors received i.v. bolus injections of tallimustine daily for 3 consecutive days. Patients were treated at six dosage levels of 33.3 micrograms/m2/day to 250 micrograms/m2/day for 3 consecutive days, with courses of therapy repeated every 28 days
Route of Administration:
Intravenous
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:04:21 GMT 2025
by
admin
on
Mon Mar 31 18:04:21 GMT 2025
|
| Record UNII |
JWV8AC9E4V
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
JWV8AC9E4V
Created by
admin on Mon Mar 31 18:04:21 GMT 2025 , Edited by admin on Mon Mar 31 18:04:21 GMT 2025
|
PRIMARY | |||
|
118438-45-2
Created by
admin on Mon Mar 31 18:04:21 GMT 2025 , Edited by admin on Mon Mar 31 18:04:21 GMT 2025
|
PRIMARY | |||
|
DBSALT002880
Created by
admin on Mon Mar 31 18:04:21 GMT 2025 , Edited by admin on Mon Mar 31 18:04:21 GMT 2025
|
PRIMARY | |||
|
6918104
Created by
admin on Mon Mar 31 18:04:21 GMT 2025 , Edited by admin on Mon Mar 31 18:04:21 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |